Eisai’s Leqembi cuts Alzheimer’s progression risk 36% versus ADNI in five-year study
BIIB•Five-year results from Leqembi’s Clarity AD extension showed a 36% reduction in Alzheimer’s progression risk versus ADNI. Eisai and Biogen said benefits were sustained for patients treated at earlier biological stages, with no new safety findings over five years.
1. Five-year results
Eisai and Biogen presented five-year results from the Clarity AD extension at the 2026 Clinical Trials on Alzheimer’s Disease conference. Continuous Leqembi treatment slowed progression compared with natural-history data, and the reported benefits increased over time.
2. Safety and early treatment
Patients treated at earlier biological stages showed sustained benefits in cognition and daily functioning. No new safety findings emerged over five years; brain swelling occurred most frequently during the first six months.




